To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
WuXi PharmaTech Begins Operation of New HPAPI Laboratory
WuXi PharmaTech (Cayman) Inc. has announced that its manufacturing subsidiary, Syn-The-All Pharmaceutical Co., Ltd. (STA), has begun operation of a high-potency active pharmaceutical ingredient (HPAPI) laboratory in Shanghai, thereby adding HPAPI processing to its portfolio of services.
The lab will support process development and clinical-trial supply of high-potency small molecules at kilogram scale.
"With the increasing use of HPAPIs in drug discovery and development, this new service augments WuXi's ability to provide highly efficient and cost-effective solutions for our partners worldwide," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
